<DOC>
	<DOC>NCT01019161</DOC>
	<brief_summary>The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML).</brief_summary>
	<brief_title>An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Patients with relapsed or refractory AML for which no standard therapies are anticipated to result in durable remission. Or, patients with newly diagnosed AML who are not considered to be suitable for standard induction and consolidation chemotherapy Ability to stay in hospital for up to 9 days on the [14C] AZD1152 treatment cycle. Subjects who have relapsed &gt; 1 year following myeloablative therapy with allogeneic bone marrow or stem cell transplantation may be eligible if they have no or limited evidence of extensive graftversushost disease QTc interval â‰¥470 ms calculated from a single ECG reading or a mean of 3 ECG readings using Fridericia's or Bazett's correction Administration of hydroxyurea to control peripheral blood counts is prohibited within 24 hours prior to first dose of study drug Any chemotherapy or radiotherapy within 14 days prior to starting the study (not including palliative radiotherapy at focal sites)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Acute Myeloid Leukaemia (AML)</keyword>
	<keyword>AML</keyword>
	<keyword>AZD1152</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>